

Robust Pipeline of Investigational Candidates

Modality Key:  Small Molecule  Peptide  Antibody  Gene Therapy

Therapeutic Area Key:  Psychiatry  Neurology  Endocrinology  Immunology

Study Initiating	Phase 1	Phase 2	Phase 3
 NBIB-'223 (Frataxin) Friedreich's Ataxia	 NBI-'569* (M1/M4 Agonist) Alzheimer's Psychosis	 direclidine* (M4 Agonist) Bipolar Mania	 direclidine* (M4 Agonist) Schizophrenia
 NBI-'188 (CRF₁ Antagonist) Women's Health	 NBI-'675 (VMAT2 Inhibitor) CNS Indications	 NBI-'570* (M1/M4 Agonist) Schizophrenia	 osavampator^{II} (AMPA PAM) Major Depressive Disorder
 NBIM-'1748 (Undisclosed) Immunology	 NBI-'355 (Nav1.2/1.6 Inhibitor) Epilepsy	 NBI-'890 (VMAT2 Inhibitor) Tardive Dyskinesia	
	 NBI-'986 (M4 Antagonist) Movement Disorders	 NBI-'567*± (M1 Preferring Agonist) Alzheimer's Cognition	
	 NBIP-'1435 (CRF₁ Antagonist) Classic Congenital Adrenal Hyperplasia		
	 NBIP-'2118 (CRF₂ Agonist) Obesity		
	 NBIP-'1968 (TG + NBIP-'2118 Combo) Obesity		
	 NBIM-'1112 (Undisclosed) Immunology		
	 NBIM-'1008 (Undisclosed) Immunology		

Neurocrine Biosciences has global rights, unless otherwise noted.
Investigational therapies are not approved for use in any country
*Licensed from Nxera Pharma.
±Nxera Pharma has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.
^{II}Takeda Pharmaceutical Company Limited has retained rights in Japan.

CRF2 = Corticotropin Releasing Factor 2; TG= Neurocrine Proprietary GIP-GLP-1-Preferring Triple Agonist ("Light" on Glucagon Activity); CRF1 = Corticotropin Releasing Factor 1; M1 = M1 Muscarinic Receptor; M4 = M4 Muscarinic Receptor; VMAT2 = Vesicular Monoamine Transporter; CNS = Central Nervous System; Nav = Sodium Channel; AMPA PAM = alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid Positive Allosteric Modulator